Jane Dancer, chief business officer at F-star—a Cambridge, UK-based biotech—chats with Mike Ward, global director of content for Informa Pharma Intelligence, on the sidelines of the recent BIO-Europe® partnering conference in Cologne, Germany. The pair discusses F-star’s asset-centric business strategy, the company’s recent deal with Denali Therapeutics and when we might see another spinout business from F-Star. The company’s recent deal is the subject of a deal case study at The One Nucleus Genesis meeting in London on December 1, 2016.
Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Jane Dancer – Chief Business Officer, F-star